BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BioNexus Gene Lab Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23+0.03 (+2.23%)
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
BioNexus Gene Lab Corp revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myanmar (Burma) | $63.72K | – | – | – | $1.83M | – | – | – | – | – | 83.7% | -96.5% |
| South Africa | $12.44K | – | – | – | $0 | – | – | – | – | – | 16.3% | – |
| Bangladesh | $0 | – | – | $78.18K | $28.85K | $0 | – | $61.88K | $88.66K | $147.29K | 0.0% | -100.0% |
| Maldives | $0 | $0 | $3.66K | $356.68K | $139.58K | $181.07K | $199.62K | $235.69K | $99.48K | $227.35K | 0.0% | -100.0% |
| Sri Lanka | $0 | $0 | $4.12K | $193.05K | $109.37K | $146.10K | $144.05K | $128.47K | $70.32K | $116.16K | 0.0% | -100.0% |
| Singapore | $0 | $0 | $664 | $108.25K | $97.62K | $34.22K | $31.53K | $439.54K | $30.73K | $70.23K | 0.0% | -100.0% |
| INDONESIA | $0 | – | $1.09K | $31.36K | $54.27K | – | $94.46K | $15.93K | – | – | 0.0% | -100.0% |
| Malaysia | – | – | – | $1.78M | $1.83M | $1.75M | $2.27M | $1.75M | $1.63M | $1.81M | – | – |
| Batam | – | – | – | – | $54.27K | $28.15K | – | – | $14.21K | $13.71K | – | – |
| Nigeria | – | – | – | $0 | $0 | – | – | $0 | $26.12K | – | – | – |
| Myanmar | – | $22.84K | $5.83M | $0 | $0 | $1.75M | $7.44M | $0 | $19.47K | – | – | – |
| Batam | – | $0 | – | – | – | $28.15K | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of BioNexus Gene Lab's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.